Regeneron Pharmaceuticals
1/10
Regeneron Pharmaceuticals has $2.0B in scheduled debt maturities. DebtCanary scores REGN at 1/10, suggesting manageable refinancing risk.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | N/A |
| Year 2 (12-24 months) | N/A |
| Year 3 (24-36 months) | N/A |
| Year 4 (36-48 months) | N/A |
| Year 5 (48-60 months) | N/A |
| Beyond 5 Years | $2.0B |
| Total Scheduled Maturities | $2.0B |
Key Metrics
How This Score Was Computed
Weighted average of 2 scored components (raw 1.00, rounded to 1). Weights of skipped components are redistributed proportionally among those scored.
| Component | Value | Sub-Score |
|---|---|---|
|
Near-Term Maturity Concentration
No Year-1 maturity bucket was reported in recent filings.
|
N/A | — |
Interest Coverage Ratio
Show calculationOperating income / Interest expense
Operating income: $3.6B
Interest expense: $73M
|
49.01x | 1/10 |
Debt-to-Equity Ratio
Show calculationLong-term debt / Stockholders' equity
Long-term debt: $2.0B
Stockholders' equity: $31.4B
No balance-sheet long-term debt figure was reported; total scheduled maturities used as the debt proxy.
|
0.06 | 1/10 |
|
Cash Coverage of Near-Term Debt
No near-term debt obligation was reported (no Year-1 maturity bucket and no balance-sheet short-term debt).
|
N/A | — |
|
Cash Runway
Only scored when a company is burning cash. Operating cash flow is positive (or unreported), so runway isn't a constraint.
|
N/A | — |
"Weight Used" shows each component's share after the weights of unscored components are redistributed. Full thresholds and formulas are on the methodology page.
Recent SEC Filings
Material disclosures from Regeneron Pharmaceuticals's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2026-03-31.
Filing date: 2026-04-29.
Data last fetched: 2026-07-26.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Regeneron Pharmaceuticals →